Methods for treating or preventing ophthalmological conditions
The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.
1. A method of treating geographic atrophy in a human subject, the method comprising administering by intravitreal injection, to said subject, 2 mg/eye of a pegylated aptamer;
wherein the aptamer comprises the sequence fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfU mGmAmGfUfUfUAfCfCfUmGfCmG-3T (SEQ ID NO: 26),
wherein fC and fU=2′-fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine, or a salt thereof;
wherein the pegylated moiety has the following structure:
wherein the pegylated aptamer is administered to the subject monthly; and
wherein the method slows or inhibits loss of visual acuity in the human subject.
2. The method of claim 1 , wherein the pegylated aptamer is administered in an aqueous solution further comprising one or more pH buffering agents and at least one tonicity adjuster.
3. The method of claim 2 , where the one or more pH buffering agents comprise dibasic sodium phosphate heptahydrate and monobasic sodium phosphate monohydrate, and the at least one tonicity adjuster comprises sodium chloride.
4. The method according to claim 1 , wherein the administration of the aptamer to the subject slows or inhibits the decrease in best corrected visual acuity as compared to a subject who is not administered the aptamer.
5. The method according to claim 1 , wherein the administration of the aptamer to the subject increases the best corrected visual acuity as compared to a subject who is not administered the aptamer.
6. The method according to claim 5 , wherein the increase is measured between baseline and at least or about 1 month.
7. The method according to claim 5 , wherein the increase is measured between baseline and at least or about 6 months.
8. The method according to claim 5 , wherein the increase is measured between baseline and at least or about 8 months.
9. The method according to claim 5 , wherein the increase is measured between baseline and at least or about 12 months.
10. The method according to claim 5 , wherein the best corrected visual acuity is measured using ETDRS letters.